Dedes KJ
Dedes KJ
University Hospital of Zurich
Verified email at usz.ch
Title
Cited by
Cited by
Year
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors
KJ Dedes, D Wetterskog, AM Mendes-Pereira, R Natrajan, MB Lambros, ...
Science Translational Medicine 2 (53), 53ra75-53ra75, 2010
2692010
Emerging therapeutic targets in endometrial cancer
KJ Dedes, D Wetterskog, A Ashworth, SB Kaye, JS Reis-Filho
Nature Reviews Clinical Oncology 8 (5), 261-271, 2011
2492011
Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer
KJ Dedes, R Natrajan, MB Lambros, FC Geyer, MA Lopez-Garcia, ...
European Journal of Cancer 47 (1), 138-150, 2011
1602011
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
KJ Dedes, PM Wilkerson, D Wetterskog, B Weigelt, A Ashworth, ...
Cell Cycle 10 (8), 1192-1199, 2011
1582011
Functional viability profiles of breast cancer
R Brough, JR Frankum, D Sims, A Mackay, AM Mendes-Pereira, I Bajrami, ...
Cancer Discovery 1 (3), 260-273, 2011
1512011
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
MD Forster, KJ Dedes, S Sandhu, S Frentzas, R Kristeleit, A Ashworth, ...
Nature Reviews Clinical Oncology 8 (5), 302-306, 2011
1172011
ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas
EP Samartzis, A Noske, KJ Dedes, D Fink, P Imesch
International Journal of Molecular Sciences 14 (9), 18824-18849, 2013
1092013
A single-cell atlas of the tumor and immune ecosystem of human breast cancer
J Wagner, MA Rapsomaniki, S Chevrier, T Anzeneder, C Langwieder, ...
Cell 177 (5), 1330-1345. e18, 2019
1082019
Loss of ARID1A expression sensitizes cancer cells to PI3K-and AKT-inhibition
EP Samartzis, K Gutsche, KJ Dedes, D Fink, M Stucki, P Imesch
Oncotarget 5 (14), 5295, 2014
942014
Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?
EP Samartzis, N Samartzis, A Noske, A Fedier, R Caduff, KJ Dedes, ...
Modern Pathology 25 (6), 885-892, 2012
892012
Impact of clinical pathways in surgery
MK Müller, KJ Dedes, D Dindo, S Steiner, D Hahnloser, PA Clavien
Langenbeck's archives of surgery 394 (1), 31-39, 2009
892009
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast
R Natrajan, PM Wilkerson, C Marchiò, S Piscuoglio, CKY Ng, P Wai, ...
The Journal of Pathology, 2014
842014
A cost-effectiveness analysis of nivolumab versus docetaxel for advanced nonsquamous NSCLC including PD-L1 testing
K Matter-Walstra, M Schwenkglenks, S Aebi, K Dedes, J Diebold, ...
Journal of Thoracic Oncology 11 (11), 1846-1855, 2016
772016
Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation
KJ Dedes, K Matter-Walstra, M Schwenkglenks, BC Pestalozzi, D Fink, ...
European Journal of Cancer 45 (8), 1397-1406, 2009
772009
Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial
KJ Dedes, TD Szucs, P Imesch, A Fedier, MK Fehr, D Fink
Annals of oncology 18 (9), 1493-1499, 2007
642007
A carcinoid tumor of the ampulla of Vater treated by endoscopic snare papillectomy
DK Pyun, G Moon, J Han, MH Kim, SS Lee, DW Seo, SK Lee
The Korean journal of internal medicine 19 (4), 257, 2004
63*2004
Management and costs of treating lung cancer patients in a university hospital
KJ Dedes, TD Szucs, S Bodis, M Joerger, A Lowy, EW Russi, HC Steinert, ...
Pharmacoeconomics 22 (7), 435-444, 2004
602004
Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland
TD Szucs, N Largeron, KJ Dedes, R Rafia, S Bénard
Current Medical Research and Opinion® 24 (5), 1473-1483, 2008
592008
PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study
MB Lambros, R Natrajan, FC Geyer, MA Lopez-Garcia, KJ Dedes, ...
Modern Pathology 23 (10), 1334-1345, 2010
542010
The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells
A Fedier, KJ Dedes, P Imesch, AO Von Bueren, D Fink
International journal of oncology 31 (3), 633-641, 2007
522007
The system can't perform the operation now. Try again later.
Articles 1–20